European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading

MT Newswires Live10-28 23:15

European equities traded in the US as American depositary receipts were little changed around 1,893.13 on the S&P Europe Select ADR Index late Wednesday morning.

From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which advanced 17% and 3.2% respectively. They were followed by healthcare tech firm Royal Philips (PHG) and medical device maker EDAP TMS (FOCL), which increased 2.2% and 1.7% respectively.

The decliners from continental Europe were led by 3D printer company Materialise (MTLS) and lender Banco Santander (SAN), which dropped 22% and 5% respectively. They were followed by consumer goods company Unilever (UL), which lost 1.7%.

The gainers from the UK and Ireland were led by Amarin (AMRN) and Biodexa Pharmaceuticals (BDRX), which rose 5.9% and 5.5% respectively. They were followed by Akari Therapeutics (AKTX) and Autolus Therapeutics (AUTL), which were up 5.1% and 1.6% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company GSK (GSK) and biopharmaceutical firm NuCana (NCNA), which fell 3.3% and 2.7% respectively. They were followed by software firm Endava (DAVA) and mining firm BHP Group (BHP), which were off 2% and 1.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment